259 related articles for article (PubMed ID: 26092960)
21. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
24. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
25. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
26. Albiglutide: first global approval.
Poole RM; Nowlan ML
Drugs; 2014 Jun; 74(8):929-38. PubMed ID: 24861909
[TBL] [Abstract][Full Text] [Related]
27. Albiglutide: a unique GLP-1 receptor agonist.
Rendell MS
Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
[TBL] [Abstract][Full Text] [Related]
28. PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
Al-Kawas F; Anderson MA; Enns R; Wilson TH; Johnson S; Mallory JM
Endocr Pract; 2019 Jul; 25(7):698-716. PubMed ID: 30865522
[No Abstract] [Full Text] [Related]
29. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.
Tomkin GH
Curr Opin Mol Ther; 2009 Oct; 11(5):579-88. PubMed ID: 19806507
[TBL] [Abstract][Full Text] [Related]
30. The safety of albiglutide for the treatment of type 2 diabetes.
Rendell MS
Expert Opin Drug Saf; 2017 Sep; 16(9):1089-1097. PubMed ID: 28678550
[TBL] [Abstract][Full Text] [Related]
31. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
St Onge EL; Miller SA
Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
[TBL] [Abstract][Full Text] [Related]
32. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
Leiter LA; Gross JL; Chow F; Miller D; Johnson S; Ahrén B;
J Diabetes Complications; 2017 Aug; 31(8):1283-1285. PubMed ID: 28587789
[TBL] [Abstract][Full Text] [Related]
33. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
[TBL] [Abstract][Full Text] [Related]
35. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
[TBL] [Abstract][Full Text] [Related]
36. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
[TBL] [Abstract][Full Text] [Related]
37. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
Home PD; Ahrén B; Reusch JEB; Rendell M; Weissman PN; Cirkel DT; Miller D; Ambery P; Carr MC; Nauck MA
Diabetes Res Clin Pract; 2017 Sep; 131():49-60. PubMed ID: 28683300
[TBL] [Abstract][Full Text] [Related]
38. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
39. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
Young MA; Wald JA; Matthews JE; Scott R; Hodge RJ; Zhi H; Reinhardt RR
Postgrad Med; 2014 Nov; 126(7):84-97. PubMed ID: 25387217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]